Evidence map›Paper›PMID 22504846›Full record

ArticleJournal of hypertension2012

Angiotensin II AT(2) receptor decreases AT(1) receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats.

Jian Yang, Caiyu Chen, Hongmei Ren, Yu Han, Duofen He, Lin Zhou, Ulrich Hopfer, Pedro A Jose, Chunyu Zeng

Open access · greenAbstract read
In one paragraph

Article in Journal of hypertension, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Effect of DCardiology discovery · 2023
    Article
  6. The Angiotensin ATPharmacological reviews · 2022
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Investigation of Receptor Heteromers Using NanoBRET Ligand Binding.International journal of molecular sciences · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Role of Thioredoxin 1 in Impaired Renal Sodium Excretion of hDJournal of the American Heart Association · 2019
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Jian YangDepartment of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, PR China.
Caiyu Chen
Hongmei Ren
Yu Han
Duofen He
Lin Zhou
Ulrich Hopfer
Pedro A Jose
Chunyu Zeng
Army Medical University · CNDaping Hospital · CNCase Western Reserve University · USUniversity of Maryland, Baltimore · US

Funding

GRK4 & Development of Salt SensitivityR01HL092196 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI ARMANDO, INES, JOSE, PEDRO A. · 2008 to 2017
$3.6M
NHLBI NIH HHS R01 HL092196NHLBI NIH HHS R01HL092196
6 · The paper itself

Abstract

backgroundThe renin-angiotensin (Ang) system controls blood pressure, in part, by regulating renal tubular sodium transport. In the kidney, activation of the angiotensin II type 1 (AT(1)) receptor increases renal sodium reabsorption, whereas the angiotensin II type 2 (AT(2)) receptor produces the opposite effect. We hypothesized that the AT(2) receptor regulates AT(1) receptor expression and function in the kidney. METHODS AND

resultsIn immortalized renal proximal tubule (RPT) cells from Wistar-Kyoto rats, CGP42112, an AT(2) receptor agonist, decreased AT(1) receptor mRNA and protein expression (P < 0.05), as assessed by reverse transcriptase-polymerase chain reaction and immunoblotting. The inhibitory effect of the AT(2) receptor on AT(1) receptor expression was blocked by the AT(2) receptor antagonist, PD123319 (10 (-6)mol/l), the nitric oxide synthase inhibitor N(w)-nitro-L-arginine methyl ester (10(-4) mol/l), or the nitric oxide-dependent soluble guanylate cyclase inhibitor 1H-[1,2,4] oxadiazolo-[4,3-a] quinoxalin-1-one (10(-5) mol/l), indicating that both nitric oxide and cyclic guanosine monophosphate (cGMP) were involved in the signaling pathway. Furthermore, CGP42112 decreased Sp1 serine phosphorylation and reduced the binding of Sp1 to AT(1) receptor DNA. Stimulation with Ang II (10(-11) mol/l per 30 min) enhanced Na(+)-K(+)-ATPase activity in RPT cells, which was prevented by pretreatment with CGP42112 (10(-7) mol/l per 24 h) (P < 0.05). The above-mentioned results were confirmed in RPT cells from AT(2) receptor knockout mice; AT(1) receptor expression and Ang II-stimulated Na-K-ATPase activity were greater in these cells than in RPT cells from wild-type mice (P < 0.05). AT(1)/AT(2) receptors co-localized and co-immunoprecipitated in RPT cells; short-term CGP42112 (10 mol/l per 30 min) treatment increased AT(1)/AT(2) receptor co-immunoprecipitation (P < 0.05).

conclusionsThese results indicate that the renal AT(2) receptor, via nitric oxide/cGMP/Sp1 pathway, regulates AT(1 )receptor expression and function, which may be important in the regulation of sodium excretion and blood pressure.

Indexed as

AnimalsBase SequenceCell Line, TransformedCyclic GMPDNA PrimersElectrophoretic Mobility Shift AssayKidney Tubules, ProximalMicroscopy, ConfocalNitric OxideOligopeptidesRatsRats, Inbred WKYReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Reverse Transcriptase Polymerase Chain ReactionSodium-Potassium-Exchanging ATPaseCGP 42112ACyclic GMPDNA PrimersNitric OxideOligopeptidesReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Sodium-Potassium-Exchanging ATPaseSp1 Transcription Factor

Identifiers

PMID22504846
PMCPMC3705562
OpenAlexW2069021638

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.